Hims & Hers Health (HIMS) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$30.92
+10.2% on the day
-46.9% over 12 months
52-week range $14.52 – $62.76
Share price and insider trades
HIMS closeInsider buyInsider sale
Bought, 12 months$1.2M
Sold, 12 months$31.2M
Insiders buying1
Insiders selling9
Hims & Hers Health insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $1.2M and 9 sold $31.2M of HIMS stock on the open market.
Get emailed when insiders cluster-buy stocks like HIMS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
HIMS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $59K | 1 |
| Q3 2026 | — | 0 | $4.3M | 13 |
| Q2 2026 | $1.2M | 1 | $7.7M | 13 |
| Q1 2026 | — | 0 | $3.7M | 8 |
| Q4 2025 | — | 0 | $16.1M | 24 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit+$323KOn all tracked purchases +27.6%
Summary
Over the past 12 months, 1 Hims & Hers Health, Inc. insider reported open-market purchases totaling $1.2M, while 9 insiders reported sales totaling $31.2M. 58 of 59 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 3,461300,809 held (−1%) | $29.17 | $101K | +6.0% | — |
| Oct 2SEC | Oluyemi OkupeCFO | Sell Plan | 2,000234,527 held (−1%) | $29.70 | $59K | +4.1% | — |
| Sep 23SEC | Oluyemi OkupeCFO | Sell Plan | 29,277236,527 held (−11%) | $29.95 | $877K | +3.2% | — |
| Sep 18SEC | Oluyemi OkupeCFO | Sell Plan | 12,313251,804 held (−5%) | $28.82 | $355K | +7.3% | — |
| Sep 17SEC | Michael ChiCOO | Sell Plan | 14,027456,660 held (−3%) | $28.39 | $398K | +8.9% | — |
| Sep 17SEC | Mohamed ElshenawyCTO | Sell Plan | 7,954185,556 held (−4%) | $28.39 | $226K | +8.9% | — |
| Sep 17SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 6,236304,270 held (−2%) | $27.86 | $174K | +11.0% | — |
| Sep 3SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 3,458310,506 held (−1%) | $28.33 | $98K | +9.1% | — |
| Aug 20SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 25,111313,964 held (−7%) | $27.55 | $692K | +12.2% | — |
| Aug 20SEC | Deborah M. AutorChief Policy Officer | Sell Plan | 16,77348,961 held (−26%) | $27.85 | $467K | +11.0% | — |
| Aug 20SEC | Oluyemi OkupeCFO | Sell Plan | 4,938264,117 held (−2%) | $29.99 | $148K | +3.1% | — |
| Aug 18SEC | Oluyemi OkupeCFO | Sell Plan | 55,383228,938 held (−19%) | $35.09 | $1.9M | -11.9% | — |
| Aug 18SEC | Oluyemi OkupeCFO | Sell Plan | 9,388264,117 held (−3%) | $27.89 | $262K | +10.9% | — |
| Jul 20SEC | Oluyemi OkupeCFO | Sell Plan | 7,163284,321 held (−2%) | $31.99 | $229K | -3.3% | — |
| Jul 7SEC | Oluyemi OkupeCFO | Sell Plan | 7,163284,321 held (−2%) | $36.49 | $261K | -15.3% | — |
| Jun 23SEC | Patrick Harrison CarrollChief Medical Officer | Sell Plan | 23,726181,861 held (−12%) | $35.00 | $830K | -11.7% | — |
| Jun 23SEC | Oluyemi OkupeCFO | Sell Plan | 18,197284,321 held (−6%) | $34.03 | $619K | -9.1% | — |
| Jun 17SEC | Mohamed ElshenawyCTO | Sell Plan | 30,040101,023 held (−23%) | $31.50 | $946K | -1.8% | — |
| Jun 17SEC | Michael ChiCOO | Sell Plan | 14,027432,124 held (−3%) | $31.50 | $442K | -1.8% | — |
| Jun 17SEC | Irene BecklundPao | Sell Plan | 7,57311,280 held (−40%) | $30.25 | $229K | +2.2% | — |
| Jun 17SEC | Irene BecklundPao | Sell Plan | 4,4906,790 held (−40%) | $31.50 | $141K | -1.8% | — |
| May 26SEC | David B WellsDirector | Buy | 48,400224,417 held (+27%) | $24.24 | $1.2M | +27.6% | — |
| May 19SEC | Oluyemi OkupeCFO | Sell Plan | 7,950262,954 held (−3%) | $23.64 | $188K | +30.8% | — |
| Apr 22SEC | Oluyemi OkupeCFO | Sell Plan | 19,645262,954 held (−7%) | $29.96 | $589K | +3.2% | — |
| Apr 22SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 9,463299,368 held (−3%) | $30.00 | $284K | +3.1% | — |
| Apr 20SEC | Oluyemi OkupeCFO | Sell Plan | 36,922281,867 held (−12%) | $25.90 | $956K | +19.4% | — |
| Apr 20SEC | Oluyemi OkupeCFO | Sell Plan | 18,005270,046 held (−6%) | $27.83 | $501K | +11.1% | — |
| Apr 7SEC | Oluyemi OkupeCFO | Sell Plan | 3,975318,789 held (−1%) | $19.98 | $79K | +54.8% | — |
| Mar 24SEC | Oluyemi OkupeCFO | Sell Plan | 9,217318,789 held (−3%) | $23.77 | $219K | +30.1% | — |
| Mar 18SEC | Michael ChiCOO | Sell Plan | 97,289407,282 held (−19%) | $24.69 | $2.4M | +25.2% | — |
| Mar 18SEC | Irene BecklundPao | Sell Plan | 5,5298,752 held (−39%) | $24.69 | $137K | +25.2% | — |
| Mar 18SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 4,812308,831 held (−2%) | $24.69 | $119K | +25.2% | — |
| Mar 2SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 4,651440,972 held (−1%) | $15.21 | $71K | +103.3% | — |
| Feb 4SEC | Oluyemi OkupeCFO | Sell Plan | 5,26291,617 held (−5%) | $26.44 | $139K | +16.9% | — |
| Jan 21SEC | Oluyemi OkupeCFO | Sell Plan | 9,06791,617 held (−9%) | $30.34 | $275K | +1.9% | — |
| Jan 7SEC | Oluyemi OkupeCFO | Sell Plan | 9,07091,617 held (−9%) | $33.79 | $306K | -8.5% | — |
| Dec 23SEC | Oluyemi OkupeCFO | Sell Plan | 23,09094,333 held (−20%) | $35.72 | $825K | -13.4% | — |
| Dec 18SEC | Michael ChiCOO | Sell Plan | 13,750305,161 held (−4%) | $36.71 | $505K | -15.8% | — |
| Dec 18SEC | Patrick Harrison CarrollChief Medical Officer | Sell Plan | 10,021169,940 held (−6%) | $36.71 | $368K | -15.8% | — |
| Dec 18SEC | Irene BecklundPao | Sell Plan | 8,4112,126 held (−80%) | $36.71 | $309K | -15.8% | — |
| Dec 18SEC | Deborah M. AutorChief Policy Officer | Sell Plan | 7,0546,175 held (−53%) | $36.71 | $259K | -15.8% | — |
| Dec 10SEC | Garcia Andrea G PerezDirector | Sell | 2,50080,166 held (−3%) | $39.17 | $98K | -21.1% | — |
| Nov 25SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 2,631153,225 held (−2%) | $35.22 | $93K | -12.2% | — |
| Nov 19SEC | Oluyemi OkupeCFO | Sell Plan | 23,18770,232 held (−25%) | $36.81 | $854K | -16.0% | — |
| Nov 12SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 2,637155,856 held (−2%) | $42.53 | $112K | -27.3% | — |
| Oct 28SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 2,637158,493 held (−2%) | $50.10 | $132K | -38.3% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 39,531161,326 held (−20%) | $62.71 | $2.5M | -50.7% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 39,332111,525 held (−26%) | $62.70 | $2.5M | -50.7% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 39,11155,947 held (−41%) | $62.70 | $2.5M | -50.7% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 17,00192,523 held (−16%) | $62.69 | $1.1M | -50.7% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 16,66792,523 held (−15%) | $62.70 | $1.0M | -50.7% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 10,469150,857 held (−6%) | $63.49 | $665K | -51.3% | — |
| Oct 20SEC | Oluyemi OkupeCFO | Sell Plan | 11,59270,232 held (−14%) | $57.13 | $662K | -45.9% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 8,42347,524 held (−15%) | $63.46 | $535K | -51.3% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 2,79292,523 held (−3%) | $62.65 | $175K | -50.6% | — |
| Oct 20SEC | Andrew DudumCEO | Sell Plan | 2,335109,190 held (−2%) | $63.39 | $148K | -51.2% | — |
| Oct 14SEC | Soleil BoughtonGeneral Counsel | Sell Plan | 2,637161,130 held (−2%) | $54.38 | $143K | -43.1% | — |
| Oct 14SEC | Michael ChiChief Commercial Officer | Sell Plan | 900291,439 held (−0%) | $58.25 | $52K | -46.9% | — |
| Oct 7SEC | Oluyemi OkupeCFO | Sell Plan | 11,59570,232 held (−14%) | $57.72 | $669K | -46.4% | — |
| Oct 2SEC | Michael ChiChief Commercial Officer | Sell Plan | 250291,439 held (−0%) | $56.00 | $14K | -44.8% | — |
Insiders at Hims & Hers Health, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Andrew DudumCEO | — | $11.0M | Oct 20, 2025 | — |
| Oluyemi OkupeCFO | — | $11.0M | Oct 2, 2026 | — |
| Michael ChiCOO | — | $3.8M | Sep 17, 2026 | — |
| David B WellsDirector | $1.2M | — | May 26, 2026 | — |
| Soleil BoughtonGeneral Counsel | — | $2.0M | Oct 2, 2026 | — |
| Patrick Harrison CarrollChief Medical Officer | — | $1.2M | Jun 23, 2026 | — |
| Mohamed ElshenawyCTO | — | $1.2M | Sep 17, 2026 | — |
| Irene BecklundPao | — | $816K | Jun 17, 2026 | — |
| Deborah M. AutorChief Policy Officer | — | $726K | Aug 20, 2026 | — |
| Garcia Andrea G PerezDirector | — | $98K | Dec 10, 2025 | — |
HIMS stock: common questions
Are Hims & Hers Health, Inc. insiders buying HIMS stock?
In the past 12 months, 1 insiders reported open-market purchases of HIMS worth $1.2M. The latest was Director David B Wells bought $1.2M of HIMS at $24.24 — first open-market purchase in our records; raises the stake by 27%.
Are Hims & Hers Health, Inc. insiders selling HIMS stock?
9 insiders reported sales worth $31.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is HIMS's 52-week range?
Over the past year HIMS has traded between $14.52 and $62.76. It last closed at $30.92 on Oct 9, 2026.